Corvus Pharmaceuticals (FRA:C17) Ending Cash Position: €16.41 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €12.47
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Ending Cash Position?

Corvus Pharmaceuticals FRA:C17 -2.88% 34 Ending Cash Position is €16.41 Mil as of Jun. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Corvus Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was €16.41 Mil.

Corvus Pharmaceuticals's quarterly Ending Cash Position increased from Dec. 2025 (€3.91 Mil) to Mar. 2026 (€34.69 Mil) but then declined from Mar. 2026 (€34.69 Mil) to Jun. 2026 (€16.41 Mil).

Corvus Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 (€11.57 Mil) to Dec. 2024 (€8.35 Mil) and declined from Dec. 2024 (€8.35 Mil) to Dec. 2025 (€3.91 Mil).

Corvus Pharmaceuticals Ending Cash Position Related Terms

Corvus Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Ending Cash Position Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.16 12.42 11.57 8.35 3.91

Corvus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.74 2.44 3.91 34.69 16.41
FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corvus Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.465+-3.557
=3.91

Corvus Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=34.809+-18.399
=16.41

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €16.41 Mil mean?
Corvus Pharmaceuticals (FRA:C17) has a Ending Cash Position of €16.41 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Ending Cash Position too high?
Corvus Pharmaceuticals' current Ending Cash Position is €16.41 Mil. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Ending Cash Position compare to MGTX and WVE?
Corvus Pharmaceuticals' Ending Cash Position of €16.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Ending Cash Position is €16.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Ending Cash Position of €16.41 Mil. The current Ending Cash Position is €16.41 Mil. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Ending Cash Position is €16.41 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.47
Price